AAPG stock news · Ascentage Pharma Group International
Get alerts for AAPG
Follow Ascentage Pharma Group International (AAPG) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AAPGAscentage Pharma will take part in two investor conferences in London soon.
NeutralAscentage Pharma said its management will attend 2 investor conferences in London, but gave no presentation details. This routine update does not change the company's outlook.
Ascentage Pharma says a trustee bought 200,000 shares to fulfill its 2022 RSU plan.
NeutralAAPG’s trustee bought existing shares for its employee plan after awards vested. The company describes this as routine administration, so it does not change the company’s business outlook.
Ascentage Pharma's drug lisaftoclax just got special approval in China to help treat certain blood cancers.
Good for AAPGAscentage Pharma received China’s Breakthrough Therapy Designation for lisaftoclax with acalabrutinib in first-line CLL/SLL. This is a favorable step, though Phase III trials continue and the designation is not an approval.
Ascentage Pharma Group holds H1 2026 earnings conference call transcript.
Good for AAPGAscentage Pharma Group's earnings call revealed a strong financial performance with a 29% increase in revenue, driven by product sales and strategic advancements in global trials. The company's focus on hematology-oncology and ongoing market expansion efforts are likely to enhance investor confidence and drive stock performance.